Atrium Therapeutics announced the dosing of the first patient in its Phase 1/2 Corventis trial for the potential treatment of PRKAG2 syndrome, targeting the genetic root cause of this rare genetic cardiomyopathy.
Atrium Therapeutics announced the dosing of the first patient in its Phase 1/2 Corventis trial for the potential treatment of PRKAG2 syndrome, targeting the genetic root cause of this rare genetic cardiomyopathy.